• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    set and indicator for drug delivery device. the present invention relates to an assembly for a drug delivery device (1), comprising a housing (2) having a proximal end and a distal end, a piston rod (8) and an indicator (13). the piston rod (8) is adapted to be moved distally in relation to the housing (2), away from a proximal starting position and towards an indication position for a first condition of the assembly in a second indication position for a first condition of the set. the piston rod (8) and the indicator (13) are configured to interact mechanically for the movement conversion of the piston rod (8) in motion of the indicator (13). a first holder (21) is provided, which is configured to releasably fix the indicator (13) in the first indication position is allowed. a second detent (22) is provided, which is configured to secure the indicator (13) in the second indication position in such a way that movement to the first indication position is prevented.
    公开号:BR112012006516B1
    申请号:R112012006516
    申请日:2010-09-21
    公开日:2019-12-31
    发明作者:Plumptre David；Jones Matthew；Veasey Robert；Giles Claughton Timothy；Terry Warren
    申请人:Sanofi Aventis Deutschland；
    IPC主号:
    专利说明:

    Invention Patent Descriptive Report for SET AND INDICATOR FOR A DRUG RELEASE DEVICE.
    Description [001] The present invention relates to a kit for a drug delivery device. In addition, the invention relates to an indicator for a drug delivery device.
    [002] In a drug delivery device, often, a plug inside a cartridge containing a plurality of doses of a drug is displaced relative to the cartridge in a distal direction by a piston rod. In this way, a dose of the drug can be expelled from the cartridge.
    [003] Drug delivery devices are described in WO 2008 / 031,238 A1 and U.S. 2007 / 0.197,976 A1, for example.
    [004] It is an objective of the present invention to provide a set and an indicator, facilitating the provision of a new, preferably improved, drug delivery device.
    [005] This objective can be achieved by the object of the inventions. Other advantageous features and modalities are the subject of the embodiments.
    [006] According to one aspect, a kit for a drug delivery device is provided. The assembly may comprise a housing. The carcass may have a proximal end and a distal end. The assembly may comprise a piston rod. The piston rod can be adapted to be moved distally with respect to the distance housing from a proximal start position and to a distal end position for the release of a drug. The set can comprise an indicator. The indicator can be adapted to indicate at least two conditions
    Petition 870190084944, of 08/30/2019, p. 11/51
    2/32 different set operation. The indicator can be movable relative to the housing from a first indication position for a first condition, for example, a condition without primer from the set to a second indication position for a second condition, for example, a condition with initial of the set. The piston rod and the indicator can be configured to interact mechanically for the conversion movement, preferably the rotation movement of the piston rod in motion, preferably the rotation movement of the indicator.
    [007] The set may comprise a first holder. The first keeper can be configured to reliably secure the indicator in the first indication position in such a way that movement to the second indication position is allowed. The assembly may comprise a second holder. The second detent can be configured to protect the indicator in the second indication position in such a way that movement to the first indication position is prevented.
    [008] Another aspect concerns an indicator for a drug delivery device. The indicator may comprise an internal member. The indicator may comprise an external display element. The external display element can provide an display surface. The outer indicating element can be elastically connected to the inner member by at least one flexible member.
    [009] Another aspect concerns an indicator for a drug delivery device. The indicator may comprise an internal member. The indicator may comprise an external display element. The external display element can provide an display surface. The outer indicating element can be elastically connected to the inner member by at least one flexible member. The indicator can comprise at least one first holder. The indicationPetition 870190084944, of 08/30/2019, p. 12/51
    3/32 pain may comprise at least one second holder. The first keeper can be adapted to allow rotation of the indicator in a first direction. The second keeper can be adapted to prevent rotation of the indicator in the opposite direction to the first direction. [0010] The drug delivery device in an expeditious manner comprises the set described above. The drug delivery device can comprise a cartridge holding a drug. The drug can be a liquid medicine, comprising, for example, GLP-1, long-acting or short-acting insulin, heparin or growth hormones. A buffer can be retained in the cartridge. The plug can seal the cartridge proximally. The drug delivery device can be an injection device. The drug delivery device may be a pen-type device, for example, an injector-type pen.
    [0011] The drug delivery device and the housing have a distal end and a proximal end. The term distal end means that the end of the drug delivery device or a component thereof, which is or is to be disposed closest to a delivery end of the drug delivery device. The term "proximal end" means the end of the device or a component thereof, which is or is to be disposed further away from the dispensing end of the device.
    [0012] According to a modality, the indicator is configured to be an initial status indicator. The first indication position can denote a condition without a device initiator. The second indication position can denote an initial condition of the device.
    [0013] When the device is not initial, there may be a gap between the piston rod and the plug. The gap may arise from tolerance
    Petition 870190084944, of 08/30/2019, p. 13/51
    4/32 manufacturing or assembly costs. At the time of drug release, the gap can reduce dose accuracy. Thus, a user can release an underdose, which can have fatal or lethal consequences.
    [0014] In order to reduce (in particular remove) the gap, the device can be started. In this way, a minimum dose of the drug, for example, a primary dose, can be fixed and dispensed from the cartridge. The indicator can be driven, in particular, rotated, by the piston rod, when the device is started, for example, when the device is switched from the condition without primer to the condition with primer. Due to the rotational movement of the indicator, the indicator is switched from the first display position, for example, a position without primer, to the second display position, for example, a position with primer. When the indicator is in the primed position, the user is indicated that the device has been started. In this way, an easy-to-use drug delivery device is achieved, providing high safety for the user. After the device is started, a first dose of the drug can be adjusted and delivered to the user.
    [0015] According to one modality, the second holder non-reliably fixes the indicator in the second indication position while the piston rod travels to the distal end position. [0016] Preferably, the indicator is releasably fixed in the first indication position by the first holder. Preferably, the indicator is maintained in a non-releasable manner in the second indication position through the second holder. Preferably, the second detent prevents rotation of the back of the indicator to the first indication position, once the device has been started. Thus, the indicator can remain in the primed position once the device has been started. Thus, the distribution of a dose
    Petition 870190084944, of 08/30/2019, p. 14/51
    5/32 additional primary and therefore the residues of a dose of the drug can be avoided. Preferably, the indicator comprises the first holder and the second holder. The first holder and the second holder may comprise or may be incorporated as a respective setback.
    [0017] According to one modality, the piston rod is rotated in a first direction of rotation with respect to the housing. The indicator can be arranged and configured to mechanically interact with the piston rod in such a way that the indicator is at least partially rotated together with the piston rod in the first direction of rotation, when the assembly switches from the first indication position to the second indication position.
    [0018] Preferably, the first direction of rotation is a direction of release. The release direction can be counterclockwise, for example. The piston rod can drive the indicator in the direction of release to switch the indicator from the first indication position to the second indication position when the device is started. In this way, the provision of an effective and easily handled drug delivery device is achieved.
    [0019] According to one modality, the first keeper comprises a ramp. The ramp can be adapted to release the indicator in the first indication position. The ramp can go up in the first direction of rotation.
    [0020] Preferably, the ramp reduces the torque required to turn the indicator in the release direction to switch the indicator from the first indication position to the second indication position. In this way, the force required for the rotation of the indicator is reduced and, therefore, the provision of an easy-to-use drug delivery device is facilitated.
    [0021] According to one modality, a member of
    Petition 870190084944, of 08/30/2019, p. 15/51
    6/32 ment is provided. A dosing button can be provided. The dosing knob can be movable in relation to the housing. The movement of the dosing button can be converted into movement of the actuating member by mechanical interaction of the dosing button and the actuating member. The movement of the dosing button in the distal direction in relation to the housing can cause the indicator to transition from the first indication position to the second indication position.
    [0022] To dispense the primary dose, the user can move the dosing knob distally in relation to the housing. The movement of the dosing button can be converted into a rotation movement of the indicator for switching the indicator in the second indication position. In this way, an easily handled drug delivery device is achieved. Additional steps required to indicate the device's operational configuration can be redundant.
    [0023] According to one embodiment, at least one counter element is provided. The counter element can be configured to engage the respective holder. Preferably, at least one counter element is part of the drive member. When the counter element engages with one of the holders, the counter element can be disengaged from the other holder.
    [0024] The counter element can be a protrusion. Preferably, when the device has no primer, the counter element engages, preferably releasably, with the first holder. The releasable coupling can allow the indicator to rotate to the second indication position when the device is started. After the device has been started, the counter element may engage, preferably in a non-releasable manner, with the second holder. In this way, the rotation of the indicator from the rear of the second indication position to the first indication position can be effectively
    Petition 870190084944, of 08/30/2019, p. 16/51
    7/32 avoided.
    [0025] According to one modality, the indicator comprises an internal member. The indicator may comprise an external display element. The inner member and the outer indicating element can be elastically connected to each other in such a way that the outer indicating element is movable with respect to the inner member when moving from the first indicating position to the second indicating position.
    [0026] Preferably, the external indication element is movable proximally to the internal member when the primary dose is released. Preferably, the inner member is a central hub. Preferably, the outer indicating element is an outer ring.
    [0027] According to a modality, the internal member and the external indication element are connected by means of at least one flexible member. When the first holder and the second holder are disengaged from the counter element, the flexible member provides a force that tends to move the indicator element in the distal direction in relation to the housing.
    [0028] To disengage the counter element from the first holder when the indicator is rotated to the second indication position, the flexible member can allow the external indication element to increase slightly in the proximal direction in relation to the internal member. Thus, the flexible member can be polarized. The flexible member can force the external indicating element back in the distal direction with respect to the internal member, to engage with the second detent after the device has been started. In this way, the flexible member provides a force to push the second holder to the counter element, to effectively and reliably hold the indicator in the second indication position.
    Petition 870190084944, of 08/30/2019, p. 17/51
    8/32 [0029] According to one embodiment, the flexible member is attached to one end face of the external indicating element. The flexible member can rotate in the radial direction in relation to the housing. The flexible member can be S-shaped.
    [0030] This can help to increase the flexibility of the flexible element and, therefore, can reduce the force that the user must apply to rotate the indicator, for example, when starting the device.
    [0031] According to one embodiment, the dosing button comprises a plurality of protrusions arranged on an internal surface of the dosing button. The protrusions can be configured to mechanically interact with at least one flexible member, such that the movement of the indicator that moves away from the second indication position and returns to the first indication position is prevented.
    [0032] When an external force is applied to bring the counter element out of the coupling with the second holder, the flexible member can lean against the protrusions. In this way, the effective length over which the flexible member is bent can be reduced and, consequently, the proximal displacement of the external indicating element can be avoided. Thus, the indicator can be effectively prevented from switching from the rear of the second display position to the first display position.
    [0033] According to a modality, the internal member is configured to cooperate with the piston rod to switch from the first indication position to the second indication position. The inner member can comprise at least one first surface. The movement of the piston rod can be converted into movement of the indicator by the mechanical cooperation of the first surface and the piston rod.
    [0034] According to one modality, the internal member with
    Petition 870190084944, of 08/30/2019, p. 18/51
    9/32 comprises at least a second surface. The mechanical cooperation of the second surface and the piston rod can keep the indicator in the first indication position.
    [0035] According to one embodiment, the first surface projects radially outwardly from the inner member. The second surface can be arranged closer to a proximal end of the piston rod than the first surface. An angular distance between the second surface and the piston rod may be less than an angular distance between the first surface and the piston rod.
    [0036] Preferably, the second surface mechanically interacts with the piston rod before the device is started, for example, in an initial state of the device, in which the piston rod is in the proximal starting position. Due to the mechanical cooperation of the second surface and the piston rod, unintentional rotation of the indicator to the second indication position, where the indicator indicates that the device has been started, can be avoided. Thus, erroneous indication of the condition started from the device before the device started is avoided.
    [0037] Preferably, the first surface mechanically interacts with the piston rod when the device is started, in particular when the primary dose is released. In this way, the rotation of the piston rod can be effectively converted into rotation of the indicator to switch the indicator from the first indication position to the second indication position.
    [0038] According to a preferred embodiment, a kit for a drug delivery device is provided. The assembly comprises a housing having a proximal end and a distal end, a piston rod, which is adapted to be displaced distally with respect to the housing distant from a proximal starting position and to a distal end position for the
    Petition 870190084944, of 08/30/2019, p. 19/51
    10/32 release of a drug, and an indicator to indicate at least two different operating conditions of the set. The indicator is movable with respect to the housing from a first indication position for a first condition of the assembly to a second indication position for a second condition of the assembly. The piston rod and indicator are configured to interact mechanically to convert movement of the piston rod into movement of the indicator. A first holder is provided, which is configured to reliably secure the indicator in the first indication position, such that movement to the second indication position is allowed, and a second holder is provided, which is configured to ensure the indicator in the second indication position, such that movement to the first indication position is prevented.
    [0039] The device, in particular the indicator, can provide clear visual signals indicating to the user whether the device is in the first condition, for example, the condition without primer, or in the second condition, for example, the condition with primer. Since the signal is preferably binary, it can be very difficult to misinterpret it. Thus, an easy-to-use and easy-to-use drug delivery device is achieved providing high safety for the user.
    [0040] Of course, the characteristics described above in connection with the different aspects and modalities can be combined with each other and with the characteristics described below.
    [0041] Additional features and refinements become evident from the following description of the exemplary modalities in connection with the accompanying figures.
    [0042] Figure 1 schematically shows a sectional perspective view of an exemplary embodiment of a drug delivery device, [0043] figure 2 schematically shows a sectional view in
    Petition 870190084944, of 08/30/2019, p. 20/51
    11/32 perspective of a part of the drug delivery device of figure 1, [0044] figure 3 schematically shows a side perspective view of a part of the drug delivery device of figure 2, [0045] figure 4 shows schematically a sectional perspective view of part of the drug delivery device of figure 3, [0046] figure 5 schematically shows a sectional perspective view of part of the drug delivery device of figure 1 in a condition without primer, [ 0047] figure 6 schematically shows a sectional perspective view of a part of the drug delivery device of figure 1 in a primed condition, [0048] figure 7 schematically shows a sectional perspective view of a part of the delivery device of drugs of figure 1, [0049] figure 8 shows schematically a top view of the part of the drug delivery device of figures 3 and 4, [005 0] figure 9 schematically shows a sectional perspective view of a part of the drug delivery device of figure 1 during the change from the primer condition to the primer condition.
    [0051] As elements, elements of the same type and elements that act in the same way can be provided with the same reference numbers in the figures.
    [0052] In figure 1, a drug delivery device 1 is shown. The drug delivery device 1 comprises a cartridge holder 3. The device 1 comprises a cartridge 4. The cartridge 4 is retained in the cartridge holder 3. The cartridge holder 3
    Petition 870190084944, of 08/30/2019, p. 21/51
    12/32 mechanically stabilizes cartridge 4.
    [0053] Cartridge 4 has a plurality of doses of a drug 31. Drug 31 is preferably a liquid drug, comprising, for example, GLP-1, insulin, short-acting or long-acting insulin, heparin or growth hormones . The term drug, as used herein, preferably means a pharmaceutical formulation containing at least one pharmaceutically active compound.
    [0054] In a modality in which the pharmaceutically active compound has a molecular weight up to 1500 Da and / or is a peptide, a protein, a polysaccharide, a vaccine, a DNA, an RNA, an enzyme, an antibody, a hormone or an oligonucleotide or a mixture of the above pharmaceutically active compound, wherein:
    [0055] in an additional embodiment, the pharmaceutically active compound is useful for the treatment and / or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus, such as diabetic retinopathy, thromboembolic disorders, such as deep vein or pulmonary thromboembolism, coronary syndrome acute (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis;
    [0056] in an additional embodiment, the pharmaceutically active compound comprises at least one peptide for the treatment and / or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus, such as diabetic retinopathy;
    [0057] in an additional embodiment, the pharmaceutically active compound comprises at least one human insulin or a human insulin analog or derivative, the glucagon-like peptide (GLP1) or an analog or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.
    Petition 870190084944, of 08/30/2019, p. 22/51
    13/32 [0058] Insulin analogues are, for example, Gly (A21), Arg (B31), human insulin Arg (B32), Lys (B3), human insulin Glu (B29), Lys (B28), human insulin Pro (B29), human insulin Asp (B28); human insulin, where proline at position B28 is replaced by Asp, Lys, Leu, Val or Ala and where at position B29 Lys can be replaced by Pro; human insulin Ala (B26); human insulin Des (B28-B30), human insulin Des (B27) and human insulin Des (B30).
    [0059] Insulin derivatives are, for example, human insulin
    B29-N-myristoil-des (B30), human insulin B29-N-palmitoyl-des (B30), human insulin B29-N-myristoil; human B29-N-palmitoyl insulin; human B28-N-myristoil insulin LysB28ProB29; human insulin B28-Npalmitoil-LysB28ProB29; human insulin B30-N-myristoilThrB29LysB30; human B30-N-palmitoyl-ThrB29LysB30 insulin; human insulin B29-N- (N-palmitoyl-Y-glutamyl) -des (B30); human insulin B29-N- (N-lithocholyl-Y-glutamyl) -des (B30); human insulin B29-N- (mcarboxyheptadecanoyl) -des (B30) and human insulin B29-N- (mcarboxyhepta-decanoyl).
    [0060] Exendin-4, for example, means exendin-4 (1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-SerLys-Gln- Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-LysAsn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser- NH2.
    [0061] Exendin-4 derivatives are, for example, selected from the following list of compounds:
    [0062] H- (Lys) 4-des Pro36, des Pro37 exendin-4 (1-39) -NH2, [0063] H- (Lys) 5-des Pro36, des Pro37 exendin-4 (1-39) - NH2, [0064] des Pro36 [Asp28] exendin-4 (1-39), [0065] des Pro36 [IsoAsp28] exendin-4 (1-39), [0066] des Pro36 [Met (O) 14, Asp28] exendin-4 (1-39), [0067] des Pro36 [Met (O) 14, IsoAsp28] exendin-4 (1-39), [0068] des Pro36 [Trp (O2) 25, Asp28] exendin-4 ( 1-39),
    Petition 870190084944, of 08/30/2019, p. 23/51
    14/32 [0069] des Pro36 [Trp (O2) 25, IsoAsp28] exendin-4 (1-39), [0070] des Pro36 [Met (O) 14 Trp (O2) 25, Asp28] exendin-4 (139 ), [0071] des Pro36 [Met (O) 14 Trp (O2) 25, IsoAsp28] exendin-4 (139), or [0072] des Pro36 [Asp28] Exendin-4 (1-39), [0073] des Pro36 [IsoAsp28] Exendin-4 (1-39), [0074] des Pro36 [Met (O) 14, Asp28] Exendin-4 (1-39), [0075] des Pro36 [Met (O) 14, IsoAsp28] Exendin-4 (1-39), [0076] des Pro36 [Trp (O2) 25, Asp28] Exendin-4 (1-39), [0077] des Pro36 [Trp (O2) 25, IsoAsp28] Exendin-4 ( 1-39), [0078] des Pro36 [Met (O) 14 Trp (O2) 25, Asp28] Exendin-4 (1-39), [0079] des Pro36 [Met (O) 14 Trp (O2) 25, IsoAsp28] Exendin-4 (1-39) [0080] wherein the Lys6-NH2 group can be attached to the C-terminus of the exendin-4 derivative;
    [0081] or a derivative of exendin-4 from the sequence [0082] H- (Lys) 6-des Pro36 [Asp28] Exendin-4 (1-39) -Lys6-NH2, [0083] des Asp28 Pro36, Pro37, Pro38Exendin -4 (1-39) -NH2, [0084] H- (Lys) 6-des Pro36, Pro38 [Asp28] Exendin-4 (1-39) -NH2, [0085] H-Asn- (Glu) 5des Pro36 , Pro37, Pro38 [Asp28] Exendin-4 (139) -NH2, [0086] des Pro36, Pro37, Pro38 [Asp28] Exendin-4 (1-39) - (Lys) 6NH2, [0087] H- (Lys) 6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4 (1-39) (Lys) 6-NH2, [0088] H-Asn- (Glu) 5-des Pro36, Pro37, Pro38 [Asp28] Exendin4 (1 -39) - (Lys) 6-NH2, [0089] H- (Lys) 6-des Pro36 [Trp (O2) 25, Asp28] Exendin-4 (1-39) Lys6-NH2, [0090] H-des Asp28 Pro36, Pro37, Pro38 [Trp (O2) 25] Exendin-4 (1Petition 870190084944, 08/30/2019, page 24/51
    15/32
    39) -NH2, [0091] H- (Lys) 6-des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28]
    Exendin-4 (1-39) -NH2, [0092] H-Asn- (Glu) 5-des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28]
    Exendin-4 (1-39) -NH2, [0093] des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28] Exendin-4 (139) - (Lys) 6-NH2, [0094] H- (Lys ) 6-des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28]
    Exendin-4 (1-39) - (Lys) 6-NH2, [0095] H-Asn- (Glu) 5-des Pro36, Pro37, Pro38 [Trp (O2) 25, Asp28]
    Exendin-4 (1-39) - (Lys) 6-NH2, [0096] H- (Lys) 6-des Pro36 [Met (O) 14, Asp28] Exendin-4 (1-39) Lys6-NH2, [ 0097] des Met (O) 14 Asp28 Pro36, Pro37, Pro38 Exendin-4 (1-39) NH2, [0098] H- (Lys) 6-desPro36, Pro37, Pro38 [Met (O) 14, Asp28] Exendin- 4 (1-39) -NH2, [0099] H-Asn- (Glu) 5-des Pro36, Pro37, Pro38 [Met (O) 14, Asp28]
    Exendin-4 (1-39) -NH2, [00100] des Pro36, Pro37, Pro38 [Met (O) 14, Asp28] Exendin-4 (139) - (Lys) 6-NH2, [00101] H- (Lys ) 6-des Pro36, Pro37, Pro38 [Met (O) 14, Asp28]
    Exendin-4 (1-39) - (Lys) 6-NH2, [00102] H-Asn- (Glu) 5 des Pro36, Pro37, Pro38 [Met (O) 14, Asp28] Exendin-4 (1-39) - (Lys) 6-NH2, [00103] H-Lys6-des Pro36 [Met (O) 14, Trp (O2) 25, Asp28] Exendin4 (1-39) -Lys6-NH2, [00104] H-des Asp28 Pro36, Pro37, Pro38 [Met (O) 14, Trp (O2) 25] Exendin-4 (1-39) -NH2, [00105] H- (Lys) 6-des Pro36, Pro37, Pro38 [Met (O) 14, Asp28]
    Petition 870190084944, of 08/30/2019, p. 25/51
    16/32
    Exendin-4 (1-39) -NH2, [00106] H-Asn- (Glu) 5-des Pro36, Pro37, Pro38 [Met (O) 14,
    Trp (O2) 25, Asp28] Exendin-4 (1-39) -NH2, [00107] des Pro36, Pro37, Pro38 [Met (O) 14, Trp (O2) 25, Asp28]
    Exendin-4 (1-39) - (Lys) 6-NH2, [00108] H- (Lys) 6-des Pro36, Pro37, Pro38 [Met (O) 14, Trp (O2) 25, Asp28] Exendin-4 (S1-39) - (Lys) 6-NH2, [00109] H-Asn- (Glu) 5-des Pro36, Pro37, Pro38 [Met (O) 14, Trp (O2) 25, Asp28] Exendin-4 ( 1-39) - (Lys) 6-NH2;
    [00110] or a pharmaceutically acceptable salt or solvate of any of the aforementioned Exedin-4 derivatives.
    [00111] Hormones are, for example, pituitary hormones or hypothalamic hormones or regulatory active peptides and their antagonists, as listed in Rote Liste, ed. 2008, chapter 50, such as Gonadotropin (folitropin, Lutropin, Choriongonadotropin, menotropin), Somatropin (somatropin), desmopressin, Terlipressin, Gonadorrelin, Triptorelin, leuprorrelin, buserelin, nafarelin, goserelin.
    [00112] A polysaccharide is, for example, a glucosaminoglycan, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or its derivative, or a sulfate, for example, a polysulfate form of the polysaccharides mentioned above, and / or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a low molecular weight polysulfated heparin is sodium enoxaparin.
    [00113] Pharmaceutically acceptable salts are, for example, acid addition salts and basic salts. The acid addition salts are, for example, HCl or HBr salts. Basic salts are, for example, salts having a cation selected from alkali or alkali, for example, Na + or K +, or Ca2 +, or an ammonium ion
    Petition 870190084944, of 08/30/2019, p. 26/51
    17/32
    N + (R1) (R2) (R3) (R4), where R1 to R4 independently of each other means: hydrogen, an optionally substituted C1 - C6-alkyl group, an optionally substituted C2-C6-alkenyl group, a C6 group -C10-optionally substituted aryl, or an optionally substituted C6-C10heteroaryl group. Other examples of pharmaceutically acceptable salts are described in Remington's Pharmaceutical Sciences, 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., USA, 1985 and in the Encyclopedia of Pharmaceutical Technology.
    [00114] Pharmaceutically acceptable solvates are, for example, hydrates.
    [00115] Cartridge 4 has an outlet 5. Drug 31 can be dispensed from cartridge 4 via outlet 5. Device 1 comprises a cap 14 that protects cartridge 4 from external influences.
    [00116] The drug delivery device 1 can be an injection device. The drug delivery device 1 can be a pen-type device, in particular a pen-type injector. Device 1 can be a disposable or reusable device. Preferably, device 1 is a fixed dose device, in particular a device configured to dispense doses of drug 31, which cannot be varied by the user. Alternatively, device 1 can be configured to dispense variable drug doses 31, preferably configurable by the user. The drug delivery device 1 can be a manually operated device, in particular not electrically.
    [00117] The drug delivery device 1 comprises a housing 2. The drug delivery device 1 and housing 2 have a distal end and a proximal end. The term distal end designates that end of the
    Petition 870190084944, of 08/30/2019, p. 27/51
    18/32 drug delivery 1 or a component thereof, which is or to be disposed closest to a drug delivery device release end 1. The distal end of device 1 is indicated by the arrow 15. The term proximal end designates that end of device 1 or a component thereof, which is or is to be arranged further away from the release end of device 1. The proximal end of device 1 is indicated by arrow 16. [00118] The drug delivery device 1 comprises a buffer 7. Buffer 7 is retained in cartridge 4. Buffer 7 is movable with respect to cartridge 4. Buffer 7 seals cartridge 4 proximally. The movement of the plug 7 in the distal direction in relation to the cartridge 4 causes the drug 31 to be released from the cartridge 4 through the outlet 5.
    [00119] Device 1 comprises a piston rod 8. The piston rod 8 operates through the casing 2 of the drug delivery device 1. The piston rod 8 rotates in a direction of release with respect to the casing 8 for the release a dose. The piston rod 8 is designed to transfer axial movement by means of the drug delivery device 1, for example, for the purpose of distributing the drug 31. In particular, the piston rod 8 is designed to transfer the force to the buffer 7, thus, pushing buffer 7 in the distal direction in relation to cartridge 4. In this way, a dose of drug 31 is dispensed from cartridge 4. The size of the dispensed dose is determined by the distance over which buffer 7 is moved in the distal direction in relation to the cartridge 4.
    [00120] Device 1 comprises a drive mechanism. The drive mechanism is arranged within the housing 2 of the drug delivery device 1. The drive mechanism comprises a dosing button 12. The dosing button 12 may comprise or may be incorporated as a sleeve. The do button
    Petition 870190084944, of 08/30/2019, p. 28/51
    19/32 sage 12 is movable with respect to housing 2. Preferably, dosing knob 12 is fluted to housing 2. Dosing knob 12 is movable proximally to housing 2 for fixing a dose of drug 31. The dosing knob 12 is movable in the distal direction in relation to the housing 2 to release the dose of drug 31. [00121] The distance by which the dosing knob 12 is moved proximally in relation to the housing 2 to fixing the dose of drug 31 can determine the dose size. A position of the proximal end and a position of the distal end of the dosing knob 12 with respect to the housing 2 are determined by a respective stopping characteristic (not explicitly shown) limiting the proximal or distal movement of the dosing knob 12 with respect to the housing 2 .
    [00122] The drive mechanism comprises a drive member 11. The drive member 11 may comprise or may be incorporated as a sleeve. The drive member 11 is axially movable with respect to the housing 2. The drive member 11 is prevented from turning with respect to the housing 11. The drive member 11 is secured against movement in relation to the dosing knob 12. Axial movement of the dosing knob 12 is converted into axial movement of the drive member 11 with respect to the housing 2.
    [00123] A force applied by the user causes the dosing knob 12 to be moved distally in relation to the housing 2 is transferred to the piston rod 8 by the actuation mechanism to dispense the dose (see figures 1 and 9) . The piston rod 8 comprises a thread 9B. Thread 9B is arranged in the proximal end section of piston rod 8. Thread 9B is formed on flexible arms of piston rod 8 (see arms 32A, 32B in figure 9). The drive member 11 comprises a mating thread 11A.
    Petition 870190084944, of 08/30/2019, p. 29/51
    20/32
    Thread 11A is arranged on an internal surface of drive member 11. Thread 11A comprises a ramp on one side. Due to the mechanical cooperation of thread 9B and mating thread 11A the axial movement of the drive member 11 is converted into rotation of the piston rod 8 in the direction of release for dispensing a dose of drug 31. The axis of rotation is a longitudinal main axis of the housing 2 or device 1. Preferably, the axis of rotation runs along the piston rod 8 and, in particular, along a main direction of extension of the piston rod 8.
    [00124] The piston rod 8 comprises an additional thread 9A. Due to the mechanical cooperation of thread 9A and the mating thread of an additional component of the drive mechanism (not explicitly shown), piston rod 8 moves distally in relation to housing 2 to distribute the dose of drug 31. Thus, from the release of a primary dose, which is explained later in greater detail, to release a last dose of drug 31 kept in cartridge 4, the piston rod 8 travels distally in relation to the housing 2 away from a proximal starting position and to a distal end position for drug release 31.
    [00125] In an initial state of device 1, for example, a condition without primer of device 1, there is a gap 33 between the piston rod 8 and the plug 7, as shown in figure 1. The gap 33 arises from manufacturing or assembly tolerances. The size of the gap 33 may vary. However, when the drug 31 is released, the gap 33 between the piston rod 8 and the plug 7 reduces the dose accuracy, because the piston rod 8 must close the gap 33 before the plug 7 is advanced and the drug 31 is expelled.
    [00126] In order to reduce (in particular to remove) the gap 33, device 1 must be primed. For device initialization
    Petition 870190084944, of 08/30/2019, p. 30/51
    21/32
    1, a minimum dose of drug 31, for example, a primary dose, is often defined and dispensed from cartridge 4. Despite the dispensation of a primary dose, the distance between piston rod 8 and plug 7 is removed and a small amount of drug 31 is dispensed from the cartridge 4. Then, the piston rod 8 abuts the plug 7, i.e., the gap 33 between the piston rod 8 and the plug 7 has been removed. After the gap 33 has been removed, device 1 is ready for fixing and delivering a first dose of drug 31 to the user.
    [00127] It is often difficult for the user to see whether device 1 has been prepared or not, that is, whether device 1 is ready to deliver the first dose. However, it is crucial for the user to know whether device 1 has been started or not, since if the user mistakenly starts device 1, and it has already been started, the user may miss a dose of drug 31. On the other hand, if the user dispenses the first dose, considering that device 1 has already been prepared, he can inject an underdose, which can have fatal or even lethal consequences for the user.
    [00128] In order to distinguish the initialized device 1 that is ready for fixation and release the first dose to the user, from the device without primer 1, for example, in order to indicate whether the primary dose has been dispensed or not, the device 1 comprises an indicator 13 (see in particular in figures 2 to 4). Indicator 13 is an initial status indicator. Indicator 13 is adapted to indicate two different operating conditions, namely, the primer condition (see figure 6) and the primer condition (see figure 5), of device 1.
    [00129] Indicator 13 is disposed in the proximal end section of device 1. Indicator 13 is retained on dosing knob 12. Indicator 13 is rotated relative to dosing knob 12 in a limited way. Indicator 13 is fixed against proximal displacement
    Petition 870190084944, of 08/30/2019, p. 31/51
    22/32 in relation to the dosing button 12 and, therefore, in relation to the actuating member 11, by means of mechanical cooperation, in particular, meeting a proximal end face of the indicator 13 with a proximal internal face 30 of the dosage 12 (see figure 2). The indicator 13 is fixed against the distal displacement in relation to the dosing button 12 and, therefore, in relation to the driving member 11, through mechanical cooperation, in particular, meeting of a face of the distal end of the indicator 13 with a face of the proximal end of the drive member 11.
    [00130] Indicator 13 is configured to mechanically cooperate with piston rod 8 when device 1 is initialized, in particular, when the primary dose is dispensed. When the piston rod 8 is rotated in the direction of release with respect to the housing 2 to dispense the primary dose, the piston rod 8 interacts with the indicator 13 such that the indicator 13 follows, in a limited way, to rotate piston rod 8 in the release direction.
    [00131] Indicator 13 comprises an internal member 18, as shown in figure 2, for example. The inner member 18 is adapted to cooperate with the piston rod 8. The indicator 13 comprises an external indicating element 17 (see figure 2 and also figures 3 and 4). The outer display element 17 is radially displaced from the inner member 18. In particular, an outer surface, for example, a display surface 17A, 17B, of the outer display element 17 is arranged closer to the inner surface of the button. dosage 12 than an external surface of the inner member 18. The inner member 18 still reaches in the proximal direction in relation to the housing 2 than the outer indicating element 17, in order to allow mechanical cooperation of the inner member 17 with the stem piston 8. The inner member 18 is partially arranged inside the outer indicating element 17. The outer indicating element
    Petition 870190084944, of 08/30/2019, p. 32/51
    23/32 no 17 may include, or may be incorporated as an outer ring. The inner member 18 may include or may be incorporated as a central hub.
    [00132] The external indicating element 17 is slightly movable axially with respect to the internal member 18 while releasing the main dose, which is explained in connection with figures 5 and 6 in more detail. The outer indicating element 17 is elastically connected to the inner member 18 by means of a plurality of flexible members 23 (see figures 3 and 4). The respective flexible member 23 is a flexible web. The flexible members 23, the inner member 18 and the external indicating element 17 are formed unitarily.
    [00133] The flexible members 23 are fixed to the face of the proximal end of the external indicating element 17 and the internal member 18. In particular, the flexible members 23 elastically connect the face of the proximal end of the internal member 18 with the face of the proximal end. of the external indicating element 17. The flexible members 23 extend in the radial direction in relation to the housing 2. The flexible members 23 are S-shaped. This can help to increase the flexibility of the flexible members 23 and, consequently, can reduce the force that the user must apply to turn the indicator 13, for example, when initializing device 1. Thus, an easy-to-use drug delivery device 1 is achieved.
    [00134] When the device 1 is mounted, in particular when the dosing knob 12 is mounted on the indicator 13, the dosing knob 12 forces the inner member 18 in the distal direction in relation to the housing 2, thus deforming the flexible members 23 This deformation tends to skew the external indicating element 17 in the direction distal to the housing 2 and distally over the drive member 11, which is explained later in greater detail.
    [00135] The inner member 18 comprises a first surface
    Petition 870190084944, of 08/30/2019, p. 33/51
    24/32 of interaction 20. The first interaction surface 20 is arranged in the distal end section of the inner member 18. The first interaction surface 20 protrudes radially outward from the inner member 18. The first interaction surface 20 and the inner member 18 are unitarily formed.
    [00136] When the piston rod 8 is rotated to dispense the primary dose, the piston rod 8, in particular the flexible arm 32A (see figure 9) of the piston rod 8 is moved towards the first interaction surface 20 until that the flexible arm 32A abuts the first interaction surface 20. When the piston rod 8 is further rotated in the direction of release with respect to housing 2, the flexible arm 32A applies a force to the first interaction surface 20 and, therefore, for indicator 13. Therefore, piston rod 8 rotates indicator 13 in the direction of release with respect to housing 2, thus switching with indicator 13 from a first indication position, for example, the position of the indicator 13, when device 1 is in the condition without primer, for a second indication position, for example, the position of indicator 13, when device 1 is in condition with primer.
    [00137] To indicate the different operating conditions, for example, the primer condition and the primer condition of device 1, the external display element 17 provides two first display surfaces 17A. The external display element 17 provides two second display surfaces 17B. The respective display surfaces 17a and 17b are different from each other. For example, the first display surface 17A may comprise a different color compared to the second display surface 17A. Preferably, the first indicating surface 17A comprises an orange or red color to indicate that the device 1 is without primer. The second display surface 17A may comprise
    Petition 870190084944, of 08/30/2019, p. 34/51
    25/32 a green or white color, to indicate that device 1 is primed.
    [00138] The first two display surfaces 17 are arranged opposite. The two second display surfaces 17B are arranged opposite. The dosing knob 12 comprises two openings 25. The two openings 25 are arranged opposite. The openings 25 axially overlap the external display element 17, in particular the respective display surfaces 17a, 17b.
    [00139] In the first indication position, for example, when the device 1 is in the condition without primer, a respective first indication surface 17A is visible through a respective opening 25. When the indicator 13 and, therefore, the element of external indication 17 is rotated to the second indication position, for example, when the device 1 is switched to the initializer condition, due to the distribution of the primary dose, a respective second interaction surface 17B is visible through a respective opening 25. In this way, the user easily recognizes which operating condition of device 1 is in, regardless of the position of device 1 in relation to the user. Thus, a very easy to use and safe drug delivery device 1 is achieved.
    [00140] When device 1 is without primer, that is, when indicator 13 is in the first indication position, the forces applied externally, such as those generated by vibration impact or adulteration of the user, can cause the indicator 13 is inadvertently rotated to the second display position such that the first display surface 17A, for example, the orange surfaces, goes out of view and in such a way that the user is mistakenly indicated that the device 1 has been started. In order to prevent the indicator
    Petition 870190084944, of 08/30/2019, p. 35/51
    26/32 is rotated in the second indication position without having initialized the device, which can have fatal consequences for the user, the internal member 18 comprises a second interaction surface 19.
    [00141] The second interaction surface 19 and the inner member 18 are formed unitarily. The second interaction surface 19 is part of a rib. The second interaction surface 19 is arranged closer to the proximal end section of the inner member 18 than the first interaction surface 20. This facilitates the interaction of the piston rod 8 and the inner member 18, when the device 1 is in the state initial, that is, when the piston rod 8 is in the proximal start position.
    [00142] The second interaction surface 19 has a smaller angular distance from the piston rod 8, in particular with respect to the flexible arm 32B of the piston rod 8 (see figure 2 and, in particular, the arrow 29 in the 8), than the first interaction surface 20 in relation to the flexible arm 32A, when the device 1 is in the initial state. Preferably, the indicator 13 is fluted to the piston rod 8 by the mechanical cooperation of the second interaction surface 19 and the flexible arm 32B. The mechanical cooperation of the second interaction surface 19 and the flexible arm 32B prevents unintentional rotation of the indicator 13 and, therefore, of the external indicating element 17 in the direction of release and, consequently, to the second indicating position when the device 1 is in the initial state. In other words, the indicator 13 is maintained in the first indication position through the mechanical cooperation of the interaction surface 19 and the piston rod 8. In addition, to keep indicator 13 in the first or second indication position, the External indication 17 comprises two first holders 21, as shown in figure 5. The respective first holder 21 is an indentation. The outer element 17 comprises two seconds holding
    Petition 870190084944, of 08/30/2019, p. 36/51
    27/32 tion 22, as shown in figure 6. The respective second holder 22 is an indentation. The respective holders 21, 22 are arranged in the distal end section of the external indicating element 17.
    [00143] The first two holders 21 are arranged in the opposite way. The two second holders 22 are arranged opposite. The first holders 21 and the second holders 22 are formed individually with the external indicating element 17. Preferably, the holders 21, 22 are molded or bleached in an external indicating element 17.
    [00144] Device 1 comprises two counter elements 24. Counter elements 24 are part of the drive member
    11. The counter elements 24 are arranged opposite. The drive member 11 and the counter elements 24 are unitarily formed. The respective counter element 24 is a protrusion protruding from the driving member 11 in the proximal direction in relation to the housing 2.
    [00145] The respective counter element 24 engages with a respective holder 21 or 22 to keep the external indication element 17 and, therefore, indicator 13 in a respective indication position. In other words, in the first display position, for example, in the position without primer, the respective counter element 24 is engaged with the respective first holder 21. In the second display position, for example, in the primer position, the respective counter element 24 is engaged with the respective second keeper 22. In particular, when the counter elements 24 are involved with the first keeper 21, the second keeper 22 is disengaged and vice versa.
    [00146] The first 21 holders comprise a ramp. The ramp rises in the direction of rotation of piston rod 8, that is, in the direction of release. The ramp is adapted to fix in a mobile way
    Petition 870190084944, of 08/30/2019, p. 37/51
    28/32 dialer 13 in the first indication position. The ramp reduces the torque required to turn the indicator 13 in the direction of release and out of engagement with the counter elements 24, while dispensing the main dose. When the indicator 13 is turned in the direction of release, the counter element 24 slides along the ramp, thus being taken out of the engagement with the holders 21.
    [00147] The flexible members 23 attached to the proximal end face of the indicating element 17 allow the external indicating element 17 to rise along the first holders 21. In other words, the flexible members 23 allow for the slight proximal movement of the indicating element external indication 17 to disengage with the counter elements 24, while dispensing the main dose, in particular, while switching indicator 13 from the first indication position to the second indication position. The flexible members 23 force the external indicating element 17, in particular the second holders 22, in cooperation with the counter elements 24 when dispensing the primary dose.
    [00148] The second detectors 22 do not comprise a ramp, but comprise lateral faces that run parallel to the main longitudinal axis of the housing 2. This helps to prevent the rotation of the indicator 13 from the rear of the second indication position to the first indication position . In this way, the second detectors 22 facilitate the releasable fixation of the indicator 13 in the second indication position while the piston rod 8 travels to the distal end position when the drug 31 is released to the user after the device 1 has been initialized.
    [00149] In order to help prevent movement of indicator 13 from the rear of the second indication position to the first indication position, the dosing knob 12 comprises a plurality of protrusions 26, which are indicated in figure 7. The protrusions are in
    Petition 870190084944, of 08/30/2019, p. 38/51
    29/32 ramp shape, the ramps grow in the direction of release. The protrusions 26 are arranged inside the dosing knob 12. The protrusions 26 are arranged on the inner proximal face 30 of the dosing knob 12. The protrusions 26 are axially aligned with the external surfaces of the flexible members 23, when the counter element 24 is engaged with the first holders 21 or with the second holders 22.
    [00150] When an external force is applied to bring the counter element 24 out of engagement with the second holders 22, for example, when the external indicating element 17 is slightly displaced proximally to the inner member 18, the middle of the flexible members 23 adjoins the protrusions 26. In this way, the effective length during which the flexible members 23 are bent is reduced and, consequently, the proximal displacement of the external indicating element 17 to bring the second holders 22 out of the engagement with the counter element 24 it is minimized or even prevented. Thus, indicator 13 is effectively prevented from switching from the rear of the second display position to the first display position.
    [00151] Likewise, protrusions 26 act to prevent the rotation of indicator 13, in a direction opposite to the release direction, to unintentionally switch indicator 13 from the first indication position to the second indication position. However, as the protrusions 26 are ramp-shaped in the direction of release, the proximal displacement of the external indicating element 17 to bring the first holders 21 out of engagement with the counter elements 24 to switch the indicator 13 from the first position of indication for the second indication position are not prevented when indicator 13 is turned in the direction of release.
    [00152] In what follows, the device initialization operation
    Petition 870190084944, of 08/30/2019, p. 39/51
    30/32 is described, as shown in figure 9:
    [00153] the user pulls the dosing knob 12 proximally to define the primary dose. The proximal movement of the dosing button 12 is converted into a proximal movement of the driving member 11 with respect to the housing 2. Indicator 13 moves proximally together with the dosing button 12 and the driving sleeve 11.
    [00154] After the primary dose has been configured, the user presses the dosing button 12 and, therefore, the driving member 11 distally. In this way, the indicator 13 is moved distally such that the first interaction surface 20 overlaps axially with the flexible arm 32A of the piston rod 8. The distal movement of the driving member 11 is converted into the distal and rotational movement of the piston rod 8 in the direction of release with respect to housing 2.
    [00155] The flexible arm 32A abuts the first interaction surface 20 and, thus, the rotation of the piston rod 8 is converted into rotation of the indicator 13 in the direction of release (see arrow 28 in figure 9); the ramp of the conditioned holders 21 thus raises the external display element 17 out of engagement with the counter elements 24, as previously described. The first display surfaces 17A are rotated out of the openings 25 and the second display surfaces 17B are rotated into the openings 25.
    [00156] The external indicating element 17 is distally biased by means of the flexible members 23 and, therefore, when the second detectors 22 reach the counter elements 24, the second detectors 22 are involved with the counter elements 24, preventing the additional rotation of indicator 13 that turns indicator 13 from the second indication position back to the first indication position. Device 1 is now in primer condition and the in
    Petition 870190084944, of 08/30/2019, p. 40/51
    31/32 dialer 13 is releasably fixed in the second indication position. [00157] Therefore, the user is indicated that device 1 has been prepared and, therefore, that device 1 is ready for fixing and dispensing the first dose of drug 31. When the first dose is defined, the first surface of interaction 20 disengages with flexible arm 32A. Thus, the mechanical cooperation of the piston rod 8 and the indicator 13 are avoided when the piston rod 8 travels to the position of the distal end to release the drug 31. The definition and dispensation of a dose of the drug 31 can occur in the same way as described for fixing and dispensing the primary dose. [00158] Device 1 described above provides clear visual signals indicating to the user whether device 1 has been initialized or not. Since the signal is binary, it is very difficult to misinterpret it. Thus, an easy to use and easily handled drug delivery device 1 is achieved. Due to the shape of the flexible members 23, device 1 minimizes the force required to initialize device 1, which is especially useful for users with reduced mobility. The indicator described above 13 is an easily manufactured component and, therefore, the cost-effective drug delivery device 1 is achieved.
    [00159] Other implementations are within the scope of the following embodiments. The elements of different implementations can be combined to form implementations not specifically described here.
    REFERENCE NUMBERS
    Drug delivery device
    Carcass
    Cartridge holder
    Cartridge
    Output
    Plug
    Petition 870190084944, of 08/30/2019, p. 41/51
    32/32
    Piston rod
    Screw thread
    Screw thread
    Trigger member
    Screw thread
    Dosing button
    Indicator
    Cover
    Distal end
    Proximal end external indication element First indication surface Second indication surface Internal member
    First interaction surface Second interaction surface First holder
    Second holder
    Flexible member
    Counter element
    Opening
    Protrusion
    Arrow
    Arrow
    Arrow
    Inner face
    Drugs
    Flexible arm
    Flexible arm
    Gap
    Petition 870190084944, of 08/30/2019, p. 42/51
    权利要求:
    Claims (5)
    [1]
    1. Set for a drug delivery device (1), comprising:
    - a carcass (2) having a proximal and a distal end,
    - a piston rod (8), which is adapted to be displaced distally in relation to the housing (2), distant from a proximal starting position and towards a distal end position for the release of a drug (31 ),
    - an indicator (13) to indicate at least two different operating conditions of the assembly, the indicator (13) being movable in relation to the housing (2) from a first indication position for a first condition of the assembly to a second position indication for a second condition of the set, being that;
    - the piston rod (8) and the indicator (13) are configured to interact mechanically for the conversion of movement of the piston rod (8) into movement of the indicator (13), characterized by the fact that
    - a first keeper (21) is provided, which is configured to releasably fix the indicator (13) in the first indication position such that movement to the second indication position is allowed, and
    - a second detent (22) is provided, which is configured to secure the indicator (13) in the second indication position, such that movement to the first indication position is prevented.
    [2]
    2/5 due to the fact that the piston rod (8) is rotatable in a first direction of rotation with respect to the housing (2) and the indicator (13) is arranged and configured to mechanically interact with the piston rod (8) such that the indicator (13) is at least partially rotated together with the piston rod (8) in the first direction of rotation, when the assembly switches from the first indication position to the second indication position.
    2. Assembly according to claim 1, characterized by the fact that the second holder (22) fixes the indicator (13) in the second indication position in a non-releasable way while the piston rod (8) moves towards the distal end position.
    [3]
    3/5 of the holders (21,22).
    8. Assembly according to any one of the preceding claims, characterized by the fact that the indicator (13) comprises an inner member (18) and an outer indicating element (17), the inner member (18) and the external indication (17) being elastically connected to each other in such a way that the external indication element (17) is movable with respect to the internal member (18) when switching from the first indication position to the second indication position.
    9. Assembly according to claim 8, characterized by the fact that the inner member (18) is configured to cooperate with the piston rod (8) to switch from the first indication position to the second indication position and the inner member (18) comprises at least one first interaction surface (20), the movement of the piston rod (8) being converted into movement of the indicator (13) through mechanical cooperation of the first interaction surface (20) and the piston rod (8).
    10. Assembly according to claim 8 or 9, characterized by the fact that the inner member (18) comprises at least a second interaction surface (19), with the mechanical cooperation of the second interaction surface (19) and the piston rod (18) keeping the indicator (13) in the first indication position.
    11. Assembly according to claim 10, characterized by the fact that the first interaction surface (20) protrudes radially outwardly from the inner member (18) and the second interaction surface (19) is arranged closer proximal end of the piston rod (8) than the first interaction surface (20), and the angular distance between the second interaction surface (19) and the piston rod (8) is less than one angular distance between the first interaction surface (20) and the
    Petition 870190084944, of 08/30/2019, p. 45/51
    3. Set, according to claim 1 or 2, featuring
    Petition 870190084944, of 08/30/2019, p. 43/51
    [4]
    4/5 piston rod (8).
    12. Assembly according to any one of claims 8 to 11, characterized in that the inner member (18) and the outer indicating element (17) are connected by means of at least one flexible member (23) and being that when the first holder (21) and the second holder (22) are disengaged from the counter element (24), the flexible member (23) provides a force that tends to move the indicator element (17) in the distal direction in relation to the housing (2).
    13. Assembly according to claim 12, characterized in that the flexible member (23) is fixed to an end face of the external indicating element (17), the flexible member (23) extending in the radial direction in relation to the carcass (2) and the flexible member (23) is S-shaped.
    14. Assembly according to claim 12 or 13, characterized in that the dosing knob (12) comprises a plurality of protrusions (26) arranged on an internal surface of the dosing knob (12), the protrusions (26 ) being configured to mechanically interact with at least one flexible member (23) in such a way that the movement of the indicator (13) that moves away from the second indication position and returns to the first indication position is prevented.
    15. Set, according to any one of the preceding claims, characterized by the fact that the indicator (13) is configured to be a primary state indicator (13) and the first indication position denotes an unprepared condition of the set and the second indication position denotes a prepared condition of the set.
    16. Indicator (13) for a drug delivery device (1), the indicator (13) comprising an inner member (18) and an external indicating element (17), the indicating element ex
    Petition 870190084944, of 08/30/2019, p. 46/51
    4. Assembly, according to claim 3, characterized by the fact that the first holder (21) comprises a ramp to releasably fix the indicator (13) in the first indication position and the ramp rising in the first direction of rotation.
    5. Assembly according to any one of the preceding claims, characterized by the fact that the indicator (13) comprises the first holder (21) and the second holder (22).
    6. Assembly according to any one of the preceding claims, characterized by the fact that it comprises a drive member (11) and a dosing button (12), the dosing button (12) being movable with respect to the housing (2), with the movement of the dosing button (12) being converted into movement of the actuating member (11) by mechanical interaction of the dosing button (12) and the actuating member (11), with the movement of the button dosing (12) in the distal direction in relation to the housing (2) causes the indicator (13) to transition from the first indication position to the second indication position.
    7. Assembly according to claim 6, characterized by the fact that it comprises at least one counter element (24) to engage the respective holder (21, 22), with at least one counter element (24) being part of the member drive (11) and when the counter element (24) engages with one of the holders (21, 22), the counter element (24) is disengaged from the other
    Petition 870190084944, of 08/30/2019, p. 44/51
    [5]
    5/5 suit (17) providing an indication surface (17A, 17B) and being elastically connected to the inner element (18) by at least one flexible member (23), characterized by the fact that the indicator (13) comprises at least a first keeper (21) and at least a second keeper (22), the first keeper (21) being adapted to allow rotation of the indicator (13) in a first direction and the second keeper (22) being adapted to prevent rotation of the indicator (13) in the opposite direction to the first direction.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012006516B1|2019-12-31|set and indicator for a drug delivery device
    AU2011209472B2|2014-07-24|Cartridge holder, drug delivery device and method for securing a cartridge in a cartridge holder
    US9592347B2|2017-03-14|Assembly for a drug delivery device, piston rod and drug delivery device
    AU2011212490B2|2014-08-21|Assembly for a drug delivery device and drug delivery device
    ES2673512T3|2018-06-22|Dose adjustment mechanism for a drug delivery device
    AU2010314169B2|2014-09-04|Assembly for a drug delivery device and drug delivery device
    BRPI1012578B1|2019-12-17|set for a drug delivery device and a drug delivery device
    US9623185B2|2017-04-18|Assembly for a drug delivery device and drug delivery device
    BR112013006964B1|2021-02-09|drive mechanism for a drug delivery device and drug delivery device
    ES2649399T3|2018-01-11|Drive assembly, drive component and medication delivery device
    US20180028757A1|2018-02-01|Drive mechanism for an injection device
    ES2650165T3|2018-01-17|Medication administration device and method for mounting a medication administration device
    ES2674594T3|2018-07-02|Drive mechanism for a drug delivery device and drug delivery device
    同族专利:
    公开号 | 公开日
    CA2772686A1|2011-03-31|
    WO2011036134A2|2011-03-31|
    JP2013505094A|2013-02-14|
    EP2480268A2|2012-08-01|
    DK2480268T3|2016-12-12|
    ES2603749T3|2017-03-01|
    CN102510761B|2014-07-16|
    CA2772686C|2018-01-02|
    HUE031031T2|2017-06-28|
    JP5875982B2|2016-03-02|
    HK1173687A1|2013-05-24|
    US9511193B2|2016-12-06|
    US20170043099A1|2017-02-16|
    WO2011036134A3|2011-06-23|
    AU2010299934A1|2012-04-12|
    AU2010299934B2|2014-08-14|
    EP2480268B1|2016-08-17|
    US10413678B2|2019-09-17|
    US20120271243A1|2012-10-25|
    PL2480268T3|2017-03-31|
    BR112012006516A2|2016-04-26|
    IL218493A|2014-07-31|
    CN102510761A|2012-06-20|
    IL218493D0|2012-04-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US533575A|1895-02-05|wilkens |
    US2695023A|1952-01-04|1954-11-23|Pfizer & Co C|Hypodermic syringe|
    CH548212A|1972-08-03|1974-04-30|Compaselect Gmbh|INJECTION SYRINGE.|
    DE3715340C2|1987-05-08|1995-10-19|Haselmeier Wilhelm Fa|Injection device|
    US4973318A|1988-02-10|1990-11-27|D.C.P. Af 1988 A/S|Disposable syringe|
    DK166948B1|1988-02-10|1993-08-09|Dcp Af 1988 As|DOSING UNIT FOR DOSING A NUMBER OF MEASURED QUANTITIES OF A FLUID, SUCH AS INSULIN, FROM A GLASS STUBLE|
    US5226895A|1989-06-05|1993-07-13|Eli Lilly And Company|Multiple dose injection pen|
    GB9007113D0|1990-03-29|1990-05-30|Sams Bernard|Dispensing device|
    EP0525525B1|1991-07-24|1995-05-03|Medico Development Investment Company|Injector|
    DK175491D0|1991-10-18|1991-10-18|Novo Nordisk As|APPARATUS|
    US5279586A|1992-02-04|1994-01-18|Becton, Dickinson And Company|Reusable medication delivery pen|
    US5391157A|1992-10-20|1995-02-21|Eli Lilly And Company|End of dose indicator|
    US5320609A|1992-12-07|1994-06-14|Habley Medical Technology Corporation|Automatic pharmaceutical dispensing syringe|
    US5383865A|1993-03-15|1995-01-24|Eli Lilly And Company|Medication dispensing device|
    ZA941881B|1993-04-02|1995-09-18|Lilly Co Eli|Manifold medication injection apparatus and method|
    US5582598A|1994-09-19|1996-12-10|Becton Dickinson And Company|Medication delivery pen with variable increment dose scale|
    CA2206734A1|1994-12-02|1996-06-06|Science Incorporated|Medicament dispenser|
    US6030363A|1994-12-02|2000-02-29|Science Incorporated|Medicament dispenser|
    AU696439B2|1995-03-07|1998-09-10|Eli Lilly And Company|Recyclable medication dispensing device|
    US5688251A|1995-09-19|1997-11-18|Becton Dickinson And Company|Cartridge loading and priming mechanism for a pen injector|
    US5674204A|1995-09-19|1997-10-07|Becton Dickinson And Company|Medication delivery pen cap actuated dose delivery clutch|
    US6110149A|1996-09-13|2000-08-29|Novo Nordisk A/S|Syringe|
    DE19730999C1|1997-07-18|1998-12-10|Disetronic Licensing Ag|Injection pen dosing selected volume of fluid, especially insulin|
    US5957896A|1997-08-11|1999-09-28|Becton, Dickinson And Company|Medication delivery pen|
    WO1999038554A1|1998-01-30|1999-08-05|Novo Nordisk A/S|An injection syringe|
    US6096010A|1998-02-20|2000-08-01|Becton, Dickinson And Company|Repeat-dose medication delivery pen|
    US6221053B1|1998-02-20|2001-04-24|Becton, Dickinson And Company|Multi-featured medication delivery pen|
    US6248095B1|1998-02-23|2001-06-19|Becton, Dickinson And Company|Low-cost medication delivery pen|
    JP2000070368A|1998-08-27|2000-03-07|Shimadzu Corp|Needle-less syringe|
    JP4290366B2|1999-08-05|2009-07-01|ベクトン・ディキンソン・アンド・カンパニー|Drug delivery pen|
    GB0002095D0|2000-01-28|2000-03-22|Novartis Ag|Device|
    GB0007071D0|2000-03-24|2000-05-17|Sams Bernard|One-way clutch mechanisms and injector devices|
    US6663602B2|2000-06-16|2003-12-16|Novo Nordisk A/S|Injection device|
    US6899699B2|2001-01-05|2005-05-31|Novo Nordisk A/S|Automatic injection device with reset feature|
    JP4283545B2|2001-05-16|2009-06-24|イーライリリーアンドカンパニー|Drug injection device with simplified reset drive assembly|
    GB0200444D0|2002-01-10|2002-02-27|Owen Mumford Ltd|Improvements relating to medical injection devices|
    WO2004007003A1|2002-07-10|2004-01-22|Novo Nordisk A/S|An injection device with a dose setting limiter|
    DE10232411A1|2002-07-17|2004-02-05|Disetronic Licensing Ag|Administration device with adjustable dosing stop|
    CA2500195C|2002-09-24|2009-07-21|Shl Medical Ab|Injecting device|
    GB0304823D0|2003-03-03|2003-04-09|Dca Internat Ltd|Improvements in and relating to a pen-type injector|
    GB2410188B|2004-01-23|2006-01-25|Medical House Plc|Injection device|
    PT1732628E|2004-03-30|2011-12-07|Lilly Co Eli|Medication dispensing apparatus with gear set having drive member accommodating opening|
    PT1732629T|2004-03-30|2019-06-07|Lilly Co Eli|Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose|
    DE102004063648A1|2004-12-31|2006-07-20|Tecpharma Licensing Ag|Injection or infusion device with life-determining device|
    US7959607B2|2005-05-27|2011-06-14|Stryker Corporation|Hand-held fluid delivery device with sensors to determine fluid pressure and volume of fluid delivered to intervertebral discs during discography|
    US7304603B2|2006-02-17|2007-12-04|Science, Engineering And Technology Associates Corporation|Radar apparatus and processing method for detecting human carried explosive devices|
    PL3626289T3|2006-09-15|2021-06-14|Ypsomed Ag|Injection device comprising an improved delivery element|
    CA2691356C|2007-06-12|2015-04-28|Becton, Dickinson And Company|Syringe with disabling mechanism|
    US8647309B2|2008-05-02|2014-02-11|Sanofi-Aventis Deutschland Gmbh|Medication delivery device|EP1476210B1|2002-02-11|2008-09-24|Antares Pharma, Inc.|Intradermal injector|
    KR20070117543A|2005-01-24|2007-12-12|앤태어스 파머, 인코퍼레이티드|Prefilled needle assisted jet injector|
    DK2058020T3|2005-02-01|2013-01-07|Intelliject Inc|Device for administering drug|
    US8361026B2|2005-02-01|2013-01-29|Intelliject, Inc.|Apparatus and methods for self-administration of vaccines and other medicaments|
    US8206360B2|2005-02-01|2012-06-26|Intelliject, Inc.|Devices, systems and methods for medicament delivery|
    US8231573B2|2005-02-01|2012-07-31|Intelliject, Inc.|Medicament delivery device having an electronic circuit system|
    US9022980B2|2005-02-01|2015-05-05|Kaleo, Inc.|Medical injector simulation device|
    WO2007131013A1|2006-05-03|2007-11-15|Antares Pharma, Inc.|Two-stage reconstituting injector|
    WO2007131025A1|2006-05-03|2007-11-15|Antares Pharma, Inc.|Injector with adjustable dosing|
    US8814834B2|2008-03-10|2014-08-26|Antares Pharma, Inc.|Injector safety device|
    ES2738539T3|2008-08-05|2020-01-23|Antares Pharma Inc|Multi dose injector|
    WO2010108116A1|2009-03-20|2010-09-23|Antares Pharma, Inc.|Hazardous agent injection system|
    US9084849B2|2011-01-26|2015-07-21|Kaleo, Inc.|Medicament delivery devices for administration of a medicament within a prefilled syringe|
    US8939943B2|2011-01-26|2015-01-27|Kaleo, Inc.|Medicament delivery device for administration of opioid antagonists including formulations for naloxone|
    US8627816B2|2011-02-28|2014-01-14|Intelliject, Inc.|Medicament delivery device for administration of opioid antagonists including formulations for naloxone|
    US8496619B2|2011-07-15|2013-07-30|Antares Pharma, Inc.|Injection device with cammed ram assembly|
    US9220660B2|2011-07-15|2015-12-29|Antares Pharma, Inc.|Liquid-transfer adapter beveled spike|
    US9486583B2|2012-03-06|2016-11-08|Antares Pharma, Inc.|Prefilled syringe with breakaway force feature|
    AU2013203784A1|2012-04-06|2013-10-24|Kaushik J. Dave|Needle assisted jet injection administration of testosterone compositions|
    WO2013169800A1|2012-05-07|2013-11-14|Antares Pharma, Inc.|Injection device with cammed ram assembly|
    US9522235B2|2012-05-22|2016-12-20|Kaleo, Inc.|Devices and methods for delivering medicaments from a multi-chamber container|
    CA2896708A1|2012-12-27|2014-07-03|Kaleo, Inc.|Devices, systems and methods for locating and interacting with medicament delivery systems|
    CA2900672C|2013-02-11|2018-03-27|Antares Pharma, Inc.|Needle assisted jet injection device having reduced trigger force|
    ES2742046T3|2013-03-11|2020-02-12|Antares Pharma Inc|Dose injector with pinion system|
    WO2014165136A1|2013-03-12|2014-10-09|Antares Pharma, Inc.|Constant volume prefilled syringes and kits thereof|
    US10117997B2|2013-03-14|2018-11-06|Norton Healthcare Limited|Dispensing mechanism for a medical device|
    GB2511806A|2013-03-14|2014-09-17|Norton Healthcare Ltd|Dispensing mechanism for a medical device|
    JP6307528B2|2013-03-14|2018-04-04|ノートン・ヘルスケア・リミテッド|Dosing mechanism for medical devices|
    US10220152B2|2013-03-14|2019-03-05|Norton Healthcare Limited|Dispensing mechanism for a medical device|
    TW201521819A|2013-09-03|2015-06-16|Sanofi Sa|Mechanism for a drug delivery device and drug delivery device comprising the mechanism|
    US9517307B2|2014-07-18|2016-12-13|Kaleo, Inc.|Devices and methods for delivering opioid antagonists including formulations for naloxone|
    WO2016110561A1|2015-01-08|2016-07-14|Novo Nordisk A/S|Drug injection device with visual end-of-contents indicator system|
    AU2016235054B2|2015-03-24|2020-07-16|Kaleo, Inc.|Devices and methods for delivering a lyophilized medicament|
    CA2990950A1|2015-06-30|2017-01-05|Kaleo, Inc.|Auto-injectors for administration of a medicament within a prefilled syringe|
    CA3046228A1|2016-12-23|2018-06-28|Kaleo, Inc.|Medicament delivery device and methods for delivering drugs to infants and children|
    EP3570906A4|2017-01-17|2020-10-21|Kaleo, Inc.|Medicament delivery devices with wireless connectivity and event detection|
    US11167087B2|2019-08-09|2021-11-09|Kaleo, Inc.|Devices and methods for delivery of substances within a prefilled syringe|
    法律状态:
    2019-01-08| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|
    2019-07-09| B06T| Formal requirements before examination|
    2019-11-05| B09A| Decision: intention to grant|
    2019-12-31| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/09/2010, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    EP09171134|2009-09-23|
    PCT/EP2010/063842|WO2011036134A2|2009-09-23|2010-09-21|Assembly and indicator for a drug delivery device|
    [返回顶部]